NCT00846274 is a Phase 1 clinical trial of SK Antithrombin III in Healthy, sponsored by SK Chemicals Co., Ltd..

Who is sponsoring NCT00846274?

NCT00846274 is sponsored by SK Chemicals Co., Ltd..

What drugs are being tested in NCT00846274?

Interventions in NCT00846274: SK Antithrombin III.

Is NCT00846274 still recruiting?

NCT00846274 is currently completed. Last updated 17 February 2009.

Last reviewed 2009-02-17 · How we verify

NCT00846274

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, "SKATIII Injection" and"ATIII Injection" in Healthy Male Subjects

Completed Phase 1 Last updated 17 February 2009

What this trial tests

Phase 1 trial testing SK Antithrombin III in Healthy in 20 participants. Completed in 1 December 2008.

Timeline

1 October 2008

Primary endpoint
1 December 2008

1 December 2008

Quick facts

Lead sponsor	SK Chemicals Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 October 2008
Primary completion	1 December 2008
Estimated completion	1 December 2008
Sites	1 location across South Korea

Drugs / interventions tested

SK Antithrombin III — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

SK Chemicals Co., Ltd. — full company profile →

Who can join

Adults 19 to 40, male only, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

ATIII activity
Time frame: within 20min after injection ATIII

Sponsor's own description

To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects.
Kim KA, Lim YY, Kim SH, Park JY. · · 2013 · cited 1× · PMID 24094463 · DOI 10.1016/j.clinthera.2013.08.018

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other SK Chemicals Co., Ltd. trials

Trials by the same sponsor.

NCT05445895 — A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke · Phase 4 · completed
NCT05453786 — A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers · Phase 1 · completed
NCT05236998 — A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers · Phase 1 · completed
NCT05906199 — A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilos · Phase 4 · completed
NCT04821687 — A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatmen · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00846274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SK Chemicals Co., Ltd.
Last refreshed: 17 February 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00846274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing